The main point of the article is not a point which is widely discussed, known, or accepted. It has nothing to do with oversight/regulation. The point is that offensive biotechnology has progressed way ahead of defensive biotechnology. In other words, we know how to engineer viruses but not how to engineer the immune system. The human immune system is vastly more complicated than viruses. Therefore, the author appears to be calling for vastly more funding into defensive biotechnology. In other words, though research into dna modification technologies (such as viral engineering) is already heavily funded, resarch into therapeutic methods and immune response should be much greater than most are even considering.

My own personal opinion is that that funding should be increased orders of magnitude; a few trillion over the next decade seems judicious.